We used, WP1066 or SC99, two inhibitors of the JAK2/STAT3 pathway capable of crossing the blood‐brain barrier and thus achieving therapeutic effects within the central nervous system (CNS),[24] to evaluate the contribution of this pathway to the display of depression (Figure 10A). Here, JAK2 is linked to depressive disorder.